Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials

Fineline Cube Jul 28, 2026
Company Drug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Fineline Cube Jul 28, 2026
Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

Fineline Cube Sep 18, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...

Company

Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland

Fineline Cube Sep 15, 2023

Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...

Company Policy / Regulatory

China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables

Fineline Cube Sep 15, 2023

The national high-value medical consumables joint procurement office has released a notification, marking the commencement...

Company

J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation

Fineline Cube Sep 15, 2023

Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...

Company Drug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

Fineline Cube Sep 15, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...

Company Drug

AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC

Fineline Cube Sep 15, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...

Company Deals

Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis

Fineline Cube Sep 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery

Fineline Cube Sep 15, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Drug

Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine

Fineline Cube Sep 15, 2023

Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...

Company Deals

Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing

Fineline Cube Sep 15, 2023

China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD...

Company R&D

Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development

Fineline Cube Sep 15, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Drug

Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA

Fineline Cube Sep 15, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...

Company Medical Device

Genesis MedTech Receives Chinese Market Approval for Antibacterial Absorbable Sutures

Fineline Cube Sep 14, 2023

Singapore-based medical device company Genesis MedTech has announced that it has received market approval in...

Company Drug

Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study

Fineline Cube Sep 14, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...

Company Deals

Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion

Fineline Cube Sep 14, 2023

Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic...

Company Deals

Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan

Fineline Cube Sep 14, 2023

A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered...

Company Drug

Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review

Fineline Cube Sep 14, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab

Fineline Cube Sep 14, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...

Company Drug

AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results

Fineline Cube Sep 14, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...

Posts pagination

1 … 506 507 508 … 700

Recent updates

  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
  • AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds
  • Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend
  • Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data
  • Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials

Company

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

Company Drug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Company Drug

Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.